Paclitaxel Hospira

Paclitaxel, the active ingredient in Paclitaxel Hospira, is a taxane presented as a sterile injectable solution for intravenous use. It is employed in the treatment of various cancers and is administered under the supervision of oncology specialists.

GNH USA supplies Paclitaxel Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Paclitaxel is a chemotherapy agent that interferes ​​    ​  ​  ​  ​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​ ​ ​ ​ ​ ​ ​ ​​  ​  ​ ​  ​  ​  ​ ​  ​ ​ ​   - Breast cancer: improves survival by inhibiting tumor cell proliferation. - Non‑small cell lung cancer: reduces tumor burden and extends progression‑free survival. - Ovarian cancer: enhances response rates when combined with platinum‑based regimens. - Gastric cancer: contributes to disease control in advanced stages. - Kaposi’s sarcoma: slows lesion growth in immunocompromised patients.

Paclitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair. - Peripheral neuropathy: tingling or numbness in hands and feet. - Nausea and vomiting: gastrointestinal upset. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis, bronchospasm, or hypotension. - Cardiotoxicity: arrhythmias or myocardial ischemia. - Severe neutropenic infection: febrile neutropenia. - Pulmonary toxicity: interstitial pneumonpac  - Hepatotoxic   - Rare skin   t

Paclitaxel   g         """"  "  "  ""  "   "  "" ""